Proton pump inhibitors (PPIs) are used in the treatment of acid-related diseases, and they have been widely used in clinical practice with the best efficacy in the last decade or so.
PPIs, i.e., H+/K+-ATPase inhibitors, have strong acid-suppressing effects with high specificity and long duration. The final step of gastric acid secretion is the exchange of intracellular H+ with tubular K+ driven by the proton pump in the gastric wall cells. PPIs block the final channel of gastric acid secretion, and compared with the previous clinical application of gastric acid inhibiting drugs-H2 receptor antagonists, the site of action is different and has different characteristics, i.e., the night time of the acid inhibition effect is good, fast onset of action, acid inhibition effect is strong and long time, easy to take, so that it can inhibit the secretion of basal gastric acid and histamine, acetylacetamide, and other gastric acid. It can inhibit the secretion of basic gastric acid and the acid secretion caused by histamine, acetylcholine, gastrin and food stimulation.
The first PPI omeprazole (omeprazole) was listed in Sweden in 1987, the second PPI lansoprazole (lansoprazole) was firstly listed in Japan in 1992, pantoprazole developed by Germany was listed in South Africa in October 1994, and a new PPI, rabeprazole (rabeprazole), was released in December 1998 in Japan. PPI rabeprazole (rabeprazole) and in August 1999 was approved by the FDA in the United States market, PPIs for the treatment of gastric and duodenal ulcers has been the status of a large number of clinical trials at home and abroad to establish, confirm.